UCB SA (EBR: UCB)
163.45
+1.85 (1.14%)
Sep 4, 2024, 3:04 PM CET
UCB SA Revenue
UCB SA had revenue of 2.79B EUR in the half year ending June 30, 2024, a decrease of -2.24%. This brings the company's revenue in the last twelve months to 5.45B, up 3.32% year-over-year. In the year 2023, UCB SA had annual revenue of 5.18B, down -4.87%.
Revenue (ttm)
5.45B
Revenue Growth
+3.32%
P/S Ratio
5.63
Revenue / Employee
606.00K
Employees
9,083
Market Cap
30.66B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5.18B | -265.00M | -4.87% |
Dec 31, 2022 | 5.45B | -330.00M | -5.71% |
Dec 31, 2021 | 5.78B | 430.00M | 8.04% |
Dec 31, 2020 | 5.35B | 434.00M | 8.83% |
Dec 31, 2019 | 4.91B | 281.00M | 6.07% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionUCB SA News
- 3 days ago - Week In Review: UCB Sells China Drug Portfolio For $680 Million To CBC - Seeking Alpha
- 9 days ago - Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies - Benzinga
- 9 days ago - Abu Dhabi fund Mubadala invests in UCB Pharma's China carve-out - Zawya
- 9 days ago - Belgium's UCB to sell China neurology and allergy business for $680 mln - Reuters
- 9 days ago - Mubadala co-invests in UCB's mature business in China to reinforce its long-term commitment to the Asian market - Zawya
- 16 days ago - United Community Banks: Preferred Share Downgrade On Low Yield - Seeking Alpha